Member Info for Agenda101

apart from bv. more green boxes.. assume it’s a reply to my post..

what a ******ed board… do these green box people have nothing better to do?

anyways good luck and happy new year to you non green box folks..

looking fwd to 2026!

Agreed, Tim. Unfortunately, the board has become a very poor place to find any meaningful or substantive discussion about Avacta. A small group of individuals, driven more by ego than constructive debate, consistently undermine the quality of conversation.

Much of the content is repetitive negativity and misinformation, which detracts from genuine analysis. It is generally clear who these contributors are, and their behaviour makes the board unproductive.

It would be far better to have an alternative forum with more mature, focused members who engage with the facts objectively rather than disputing established information endlessly. As it stands, the board offers little value to anyone seeking serious insight into Avacta.

So many green boxes..

LTH GL!

It’s gone worse again! Everytime Avacta release incredible news the share price drops considerably.. it’s pretty consistent..

the only WAY is to move the ava6000 on fast track or licences out… it has been 4 years and surely the data should be enough unless they have not done there diligence..

Farm out the ava6000 and then and only then we see a rise in the SP..

Albiet the more data the better price..

Seems like it’s going to take a lot more time so funding will need to be sorted early 2026…

Feels like another 2 years away now… sort it out Avacta!

Https://x.com/avacta/status/2001593953091518813?s=46&t=duWTVR3YhEB6IsWdJtkMpQ

Our trip to Glasgow to view the manufacturing of AVA6103 was a huge success. Sharing our new data and their new data are key signs of a great collaboration. This joint team is full of top notch folks and we are thrilled to move ahead with them in the program.

#LetsDoThis

Can’t wait for results tomorrow. The SP won’t move in my opinion unless there is a sense of : fast track approval, license deals etc…

We know it’s going to be above and beyond the “standard of care” for SGC…

Data only doesn’t move the SP, not in this company..

But some incredible data could shift it!

Come on Avacta.. deserve something for Christmas!

Hopefully give us a sense of

It is widely acknowledged that what they are achieving is extraordinary—groundbreaking by any measure. The true question now is not if it will happen, but when.

that’s was **** vocab!

We all know it’s incredible what they are achieve and groundbreaking to say the least..

When is it all going to happen, that’s the question?

Business Development teams from pharma and CROs use the summit to:

• Explore co-development

• License novel models

• Start fee-for-service collaborations

• Discuss joint validation studies

Have a great day all!

This Thursday.

#AVCT is an "unmissable event highlight" at the Tumour Models Summit, London

I’ve shared a video thread that many of us have likely seen before, but it remains valuable, especially for newcomers, as it features a positive and informative interview with the CEO.

What’s increasingly frustrating is seeing threads like this repeatedly derailed by the same individuals, whose responses often seem driven more by ego than by genuine insight. There appears to be a constant need to be the first to criticise, argue, or dismiss, rather than to contribute constructively.

This behavior adds no value and discourages meaningful engagement. If we want this community to remain informative and worth participating in, we need to focus on respectful, thoughtful dialogue, not ego-driven negativity.

That said, I’ve been here long enough to know this pattern likely won’t change. Perhaps it’s time some people focused their energy on something more productive, maybe even a job!

Curtesy of Tom.

This is good enough for me..

looking fwd to the next couple months!

https://x.com/tom_the_bomb__/status/1992139418162053577?s=46&t=duWTVR3YhEB6IsWdJtkMpQ

According to analyst firm Trinity Delta, they value Avacta Plc at £449 million, equivalent to 119 pence per share (or roughly 112 pence per share fully diluted).

😉

71p

CC comments “ A New World For Avacta”!

Https://avacta.com/research-development-spotlight-series-episode-12/

In the case of AVA6000, it appears most probable that its clinical application will involve combination therapy with Keytruda, aligning with the established Keynote-522 regimen in which doxorubicin is administered subsequent to Keytruda???🙃

Evidence chain (key sources)

1. LY4337713 study titled FiREBOLT (registry shows LY4337713 is for FAP-positive solid tumours). 

2. Avacta press release (Jan 2021) — Avacta licensed its pre|CISION (FAP-activated/tumour-activated radiopharmaceutical) technology to POINT. 

3. POINT materials / press — POINT described the PNT2004 program and its lead candidate PNT6555 (a Lu-177 FAP radioligand) and noted use of CanSEEK / pre|CISION in their programs. 

4. Lilly corporate materials & acquisition filings — Lilly acquired POINT (closed Dec 27, 2023) and lists a [Lu-177]-FAP molecule in its pipeline (consistent with LY4337713 being Lilly’s FAP radioligand).

Stop it!